DDInter1594 DDInter1628
Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome (FCAS) and Muckle-Wells Syndrome (MWS), in adults and children greater than 12 years old.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Rilonacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dactinomycin
Dactinomycin {u} (Compound) upregulates {v} (Gene) DNM1
DNM1 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Rilonacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clonazepam
Clonazepam {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Rilonacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dactinomycin
Dactinomycin {u} (Compound) downregulates {v} (Gene) PLK1
PLK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Rilonacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Altretamine
Altretamine {u} (Compound) causes {v} (Side Effect) Thrombocytopenia
Thrombocytopenia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Rilonacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dactinomycin
Dactinomycin {u} (Compound) upregulates {v} (Gene) PHKG2
PHKG2 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Rilonacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dactinomycin
Dactinomycin {u} (Compound) downregulates {v} (Gene) FOXJ3
FOXJ3 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Rilonacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Prednisone
Prednisone {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Rilonacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Norethisterone
Norethisterone {u} (Compound) upregulates {v} (Gene) NFKBIA
NFKBIA {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Rilonacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Prednisone
Prednisone {u} (Compound) downregulates {v} (Gene) ZDHHC6
ZDHHC6 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Rilonacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Nilotinib {u} (Compound) is included by {v} (Pharmacologic Class) Protein Kinase Inhibitors
Protein Kinase Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Ruxolitinib
Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Dactinomycin and Dactinomycin (Compound) upregulates DNM1 (Gene) and DNM1 (Gene) is downregulated by Ruxolitinib (Compound)
Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Clonazepam and Clonazepam (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Dactinomycin and Dactinomycin (Compound) downregulates PLK1 (Gene) and PLK1 (Gene) is bound by Ruxolitinib (Compound)
Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Altretamine and Altretamine (Compound) causes Thrombocytopenia (Side Effect) and Thrombocytopenia (Side Effect) is caused by Ruxolitinib (Compound)
Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Dactinomycin and Dactinomycin (Compound) upregulates PHKG2 (Gene) and PHKG2 (Gene) is bound by Ruxolitinib (Compound)
Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Dactinomycin and Dactinomycin (Compound) downregulates FOXJ3 (Gene) and FOXJ3 (Gene) is upregulated by Ruxolitinib (Compound)
Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Norethisterone and Norethisterone (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is upregulated by Ruxolitinib (Compound)
Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone (Compound) downregulates ZDHHC6 (Gene) and ZDHHC6 (Gene) is downregulated by Ruxolitinib (Compound)
Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib (Compound) is included by Protein Kinase Inhibitors (Pharmacologic Class) and Protein Kinase Inhibitors (Pharmacologic Class) includes Ruxolitinib (Compound)